论文部分内容阅读
我院2010年1月至2012年6月收治的2型糖尿病患者86例,均联合口服格列美脲和拜糖平治疗,观察治疗前后空腹血糖、三餐后2h平均血糖、糖化血红蛋白的变化及不良反应。结果:治疗后空腹血糖、三餐后2h平均血糖、糖化血红蛋白水平均较治疗前显著降低(P<0.01)。结论:格列美脲是一种安全有效的磺脲类降糖药物,与阿卡波糖联合应用对2型糖尿病的临床疗效显著,安全性高,值得临床广泛应用。
In our hospital from January 2010 to June 2012 86 patients with type 2 diabetes were treated with oral glimepiride and orally administered to observe the fasting blood glucose before and after treatment, 2h after meals average blood glucose, changes in hemoglobin A1c And adverse reactions. Results: After treatment, fasting blood glucose, mean blood glucose and HbA1c at 2h after meals were significantly lower than those before treatment (P <0.01). Conclusion: Glimeporide is a safe and effective sulfonylurea hypoglycemic drug. The combination therapy with acarbose has obvious clinical efficacy and safety for type 2 diabetes mellitus, and it is worth widely clinical application.